Skip to main content

Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

The Original Article was published on 14 September 2022

Correction: BMC Cancer 22, 982 (2022)

https://doi.org/10.1186/s12885-022-10070-z

Following publication of the original article [1], the authors identified an error in Fig. 1B. Patients with EZH2 mutation (n=7) have worse prognosis than patients without mutation (n=23). The updated Fig. 1 is supplied in this correction article.

Fig. 1
figure 1

Kaplan-Meier curves in patients with grade 1, 2, and 3a. A PFS and OS in patients treated with R-CHOP (EZH2 mutated vs. unmutated); B PFS and OS in patients treated with R-Bendamustine (EZH2 mutated vs. unmutated). C PFS and OS in EZH2 mutated patients (R-CHOP vs. R-Bendamustine). PFS Progression-free survival. OS: Overall survival

The original article [1] has been corrected.

Reference

  1. Martínez-Laperche C, Sanz-Villanueva L, Díaz Crespo FJ, et al. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. BMC Cancer. 2022;22:982. https://doi.org/10.1186/s12885-022-10070-z.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Bastos Oreiro.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Martínez-Laperche, C., Sanz-Villanueva, L., Díaz Crespo, F.J. et al. Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. BMC Cancer 22, 1224 (2022). https://doi.org/10.1186/s12885-022-10335-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12885-022-10335-7